Regenerative Immunotherapy Potency Quantification via Multi-Assay Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying the potency of regenerative immunotherapies face challenges in ensuring batch-to-batch consistency due to complex biological mechanisms and variability in therapeutic effects, making it difficult to identify reliable biological markers for assessing therapeutic activity.
Innovation Solution
The development of methods that assess the potency of regenerative immunotherapies through quantification of growth factor production, immune regulatory factor production, and ability to reduce apoptosis or induce regeneration in target tissue cells, using specific assays such as stimulation of angiogenesis in human umbilical vein endothelial cells and cytokine production profiling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional potency assays are used to assess regenerative immunotherapies, then batch-to-batch consistency can be evaluated, but the assays fail to reliably predict therapeutic activity due to complex biological mechanisms and variability in therapeutic effects
Solution Approach 1:
The patent segments the complex biological assessment into multiple distinct functional assays: (1) mitogenic activity assay measuring proliferation of target tissue cells, (2) anti-apoptotic activity assay measuring protection from cell death, and (3) regenerative activity assay measuring tissue repair capacity. Each assay evaluates a specific biological function independently, making the overall potency assessment more reliable despite the complexity of regenerative mechanisms
Solution Approach 2:
The patent changes the measurement parameters from traditional single-endpoint assays to multiple functional parameters including cell proliferation rate, apoptosis resistance level, and regenerative capacity metrics. This multi-parameter approach captures the complexity of regenerative immunotherapy mechanisms while providing reliable potency prediction through comprehensive functional assessment
2Measurement precision
If multiple functional assays are implemented to assess different biological markers, then therapeutic activity prediction improves, but the assessment methodology becomes more complex
Solution Approach 1:
The patent develops universal assay platforms that can evaluate multiple biological markers and functions within integrated systems. The mitogenic assay, anti-apoptotic assay, and regenerative assay are designed as complementary functional tests that collectively assess therapeutic potency across different biological mechanisms, making marker identification more systematic and less difficult
Solution Approach 2:
The patent uses standardized target tissue cell lines and conditioned media systems as intermediaries to translate complex biological mechanisms into measurable functional outputs. These intermediary systems bridge the gap between complex in vivo regenerative processes and in vitro measurement capabilities, enabling precise therapeutic activity prediction through controlled functional assessments
3Manufacturing precision
If potency assays focus on specific biological functions such as mitogenic activity or anti-apoptotic activity, then relevant therapeutic properties are measured, but the overall potency assessment requires integration of multiple complex pathways
Solution Approach 1:
The patent employs dynamic assessment strategies where assays are performed at multiple time points and under varying stimulation conditions to capture the temporal and contextual nature of biological pathways. This dynamic approach integrates complex pathway interactions while maintaining manufacturing precision by establishing consistent temporal profiles for potency comparison across production batches
Data Source
AI summary
Disclosed are means, methods and compositions of matter useful for quantifying the potency of regenerative therapeutics based on utilization of immunotherapies to induce tissue repair. In one embodiment said immunotherapy with regenerative activity is a T regulatory cell based therapy for stroke whose potency is quantified by assessment of one or more from the following: a) basal production of regenerative factors; b) induced production of regenerative factors; c) ability to prevent apoptosis of a target cell of interest; d) ability to stimulation proliferation of a target cell; and e) ability to induce proliferation of a progenitor cell belonging to tissue type of which therapy is desired.